Streetwise Regenerative Medicine Articles


News Update

Cell Therapy Company and Chinese Firm Sign Marketing Deal

  ()
This biotech, in Phase 1 development of regenerative technologies addressing skin and orthopedic indications, has finalized a commercialization deal with YOFOTO. read more >

Target Price Increased on Biotech After Q2/18 Revenue Record, Beat

Research Report
  ()
A Maxim Group report explained the likely reasons behind revenue growth for the firm, which produces media used in development of cell therapies. read more >
Management Q&A: View from the Top

Cancer in the Crosshairs: IMV Looks to Deliver Immunotherapy a New Way

Managment Q&A: View from the Top
  ()
In this interview with The Life Sciences Report, IMV Inc.'s CEO Fred Ors and Pierre Labbè, chief financial officer, describe the innovative immunotherapy platform technology that has attracted partnerships with big pharma, prompted reorganization of the company, and holds long-term promise for cancer patients. read more >

What Stephen Hawking Missed: Small Biotechs Developing Promising Cell Therapies for Devastating Disease

  ()
In the second of a two-part series exploring the disruptive cell therapy space, Maxim Group analyst Jason McCarthy takes a look at small-cap companies targeting big-ticket indications and their potential to drive blockbuster value for both patients and investors. read more >

Risk Versus Reward: The Value of Cell Therapy for Patients and Investors

  ()
The cell therapy space, encompassing disruptive new treatment including stem cell therapy, immunotherapy and gene editing, has begun to mature, with a handful of product approvals and others in late-stage development. In the first of a two-part series examining the disruptive technology, Maxim Group analyst Jason McCarthy exposes the upsides and downsides of the space, and the companies at its forefront. read more >

Convergence Will Drive the Ultimate Disruption of Life Sciences

Contributed Opinion
  ()
Andrea Bartzen, a strategic commercial and communication consultant, describes the disruptive technologies positioned to radically alter the business of life sciences as discussed at a recent BIO CEO Summit Investor Night. read more >

Coverage Launched on Biotech That Could 'Disrupt the Skin Regeneration Market'

Research Report
  ()
Elemer Piros, a Cantor Fitzgerald analyst, explained this company's lead product, including how it works, its success to date and its market potential. read more >

Analyst's $70 Target Price on Regenerative Medicine Biotech More than a Triple

  ()
One analyst believes an innovative biotech company that has developed groundbreaking technology to change the way doctors perform body tissue engineering, like skin grafting on burn victims, has the potential to "revolutionize the field of regenerative medicine." read more >
Showing Results: 1 to 8 of 8

Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

More Experts

"We are initiating coverage on PMN." ❭
– John Vandermosten, Zacks Small-Cap Research
"We continue to view DRRX as undervalued and reiterate our Buy rating." ❭
– Francois Brisebois, Laidlaw & Company
"SPR's acquisition in the pipeline creates water-soluble cannabis." ❭
– Chris Parry, Equity Guru